Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +62.18%
#3 MetaDAO MetaDAO +28.24%
#4 Pons Pons +27.98%
#5 Rain Rain +23.16%
#6 Bedrock Bedrock +20.46%
#7 Ontology Gas Ontology Gas +18.79%
#8 Prom Prom +14.96%
#9 Humanity Humanity +14.75%
#10 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +13.68%
Coin of the day
QuantixAI QuantixAI
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
CG Oncology Inc. CG Oncology Inc.

CG Oncology Inc.

CGON
Rang in Aktien #2843
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops... CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Aktienkurs
$78.86
Marktkapitalisierung
$6.96B
Veränderung (1 Tag)
0.80%
Veränderung (1 Jahr)
210.23%
Land
US
Handel CG Oncology Inc. (CGON)

Kategorie

Healthcare
Kursverlauf für CG Oncology Inc. (CGON)
Höchster Schlusskurs: $77.06 am 2026-08-01

Niedrigster Schlusskurs: $36.59 am 2024-01-01
Kursverlauf der Aktie von CG Oncology Inc. von 2024 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 34.54%
2025 32.36%
2024 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 50.56%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 525.80%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.47 -12.71%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $772.27 8.67%
CH